Copyright
©The Author(s) 2018.
World J Transplantation. Sep 10, 2018; 8(5): 122-141
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.122
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.122
Table 4 Genotype-phenotype correlations in atypical hemolytic uremic syndrome (data refer to the period before introduction of eculizumab)
Gene | Risk of death or ESRD at onset or first yr | Risk ofrecurrence | Risk of death or ESRDafter 3-5 yr | Risk of recurrencein allograft |
CFH or CFH-CFHR1/3 hybrid genes | 50%-70% | 50% | 75% | 75%-90% |
CFI | 50% | 10%-30% | 50%-60% | 45%-80% |
MCP single | 0%-6% | 70%-90% | 6%-38% | < 20% |
MCP combined1 | 30%-40% | 50% | 50% | 50%-60% |
C3 | 60% | 50% | 75% | 40%-70% |
CFB | 50% | 100% | 75% | 100% |
THBD | 50% | 30% | 54% | ? |
Anti-FH | 30%-40% | 40%-60% | 35%-60% | Depends on antibody titers |
- Citation: Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141
- URL: https://www.wjgnet.com/2220-3230/full/v8/i5/122.htm
- DOI: https://dx.doi.org/10.5500/wjt.v8.i5.122